BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 32083759)

  • 21. Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice.
    Clar J; Mutel E; Gri B; Creneguy A; Stefanutti A; Gaillard S; Ferry N; Beuf O; Mithieux G; Nguyen TH; Rajas F
    Hum Mol Genet; 2015 Apr; 24(8):2287-96. PubMed ID: 25561689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
    Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
    J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.
    Yavarow ZA; Kang HR; Waskowicz LR; Bay BH; Young SP; Yen PM; Koeberl DD
    Hum Mol Genet; 2020 Jan; 29(2):286-294. PubMed ID: 31816064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context.
    Monteillet L; Gjorgjieva M; Silva M; Verzieux V; Imikirene L; Duchampt A; Guillou H; Mithieux G; Rajas F
    Mol Metab; 2018 Oct; 16():100-115. PubMed ID: 30100243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocytes contribute to residual glucose production in a mouse model for glycogen storage disease type Ia.
    Hijmans BS; Boss A; van Dijk TH; Soty M; Wolters H; Mutel E; Groen AK; Derks TGJ; Mithieux G; Heerschap A; Reijngoud DJ; Rajas F; Oosterveer MH
    Hepatology; 2017 Dec; 66(6):2042-2054. PubMed ID: 28727166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disturbed lipid metabolism in glycogen storage disease type 1.
    Bandsma RH; Smit GP; Kuipers F
    Eur J Pediatr; 2002 Oct; 161 Suppl 1():S65-9. PubMed ID: 12373575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels.
    Saeed A; Hoogerland JA; Wessel H; Heegsma J; Derks TGJ; van der Veer E; Mithieux G; Rajas F; Oosterveer MH; Faber KN
    Hum Mol Genet; 2020 Jan; 29(2):264-273. PubMed ID: 31813960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Protective Role of the Carbohydrate Response Element Binding Protein in the Liver: The Metabolite Perspective.
    Agius L; Chachra SS; Ford BE
    Front Endocrinol (Lausanne); 2020; 11():594041. PubMed ID: 33281747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review.
    Cho JH; Weinstein DA; Lee YM
    J Inherit Metab Dis; 2021 Jan; 44(1):118-128. PubMed ID: 32474930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome.
    Iizuka K; Horikawa Y
    Endocr J; 2008 Aug; 55(4):617-24. PubMed ID: 18490833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Causative and Sanative dynamicity of ChREBP in Hepato-Metabolic disorders.
    Daniel PV; Mondal P
    Eur J Cell Biol; 2020 Nov; 99(8):151128. PubMed ID: 33232883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression.
    Dentin R; Pégorier JP; Benhamed F; Foufelle F; Ferré P; Fauveau V; Magnuson MA; Girard J; Postic C
    J Biol Chem; 2004 May; 279(19):20314-26. PubMed ID: 14985368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver ChREBP Protects Against Fructose-Induced Glycogenic Hepatotoxicity by Regulating L-Type Pyruvate Kinase.
    Shi JH; Lu JY; Chen HY; Wei CC; Xu X; Li H; Bai Q; Xia FZ; Lam SM; Zhang H; Shi YN; Cao D; Chen L; Shui G; Yang X; Lu Y; Chen YX; Zhang WJ
    Diabetes; 2020 Apr; 69(4):591-602. PubMed ID: 31974143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas.
    Mutel E; Abdul-Wahed A; Ramamonjisoa N; Stefanutti A; Houberdon I; Cavassila S; Pilleul F; Beuf O; Gautier-Stein A; Penhoat A; Mithieux G; Rajas F
    J Hepatol; 2011 Mar; 54(3):529-37. PubMed ID: 21109326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
    Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
    Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice.
    Linden AG; Li S; Choi HY; Fang F; Fukasawa M; Uyeda K; Hammer RE; Horton JD; Engelking LJ; Liang G
    J Lipid Res; 2018 Mar; 59(3):475-487. PubMed ID: 29335275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fructose 2,6-bisphosphate is essential for glucose-regulated gene transcription of glucose-6-phosphatase and other ChREBP target genes in hepatocytes.
    Arden C; Tudhope SJ; Petrie JL; Al-Oanzi ZH; Cullen KS; Lange AJ; Towle HC; Agius L
    Biochem J; 2012 Apr; 443(1):111-23. PubMed ID: 22214556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mice expressing reduced levels of hepatic glucose-6-phosphatase-α activity do not develop age-related insulin resistance or obesity.
    Kim GY; Lee YM; Cho JH; Pan CJ; Jun HS; Springer DA; Mansfield BC; Chou JY
    Hum Mol Genet; 2015 Sep; 24(18):5115-25. PubMed ID: 26089201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia.
    Gjorgjieva M; Calderaro J; Monteillet L; Silva M; Raffin M; Brevet M; Romestaing C; Roussel D; Zucman-Rossi J; Mithieux G; Rajas F
    J Hepatol; 2018 Nov; 69(5):1074-1087. PubMed ID: 30193922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.
    Waskowicz LR; Zhou J; Landau DJ; Brooks ED; Lim A; Yavarow ZA; Kudo T; Zhang H; Wu Y; Grant S; Young SP; Huat BB; Yen PM; Koeberl DD
    Hum Mol Genet; 2019 Jan; 28(1):143-154. PubMed ID: 30256948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.